This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Compact view

Research pass: medium Compound WATCH-LIST HIGH

Dapoxetine

Extended Research

◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Editor's verdict WATCH-LIST HIGH

Premature ejaculation is not a stated indication for the user (20yo MMA athlete + business owner). If PE ever became an issue, dapoxetine is the cleanest tool by a wide margin — it is the only PE-specific approved drug, dosed on-demand rather than chronically, and avoids the chronic-SSRI side-effect profile (libido suppression, emotional blunting, weight gain, withdrawal) that off-label chronic paroxetine/sertraline/fluoxetine impose. Verdict would shift to OPTIONAL-ADD if PE became a concern, and to PRIMARY-PICK in that scenario for short-term use.

Research pass: medium

▸ Decision matrix by user profile Per-archetype

Archetype	Verdict	Rationale
★20-30, brain-priority, high cognitive workload, no PE complaint (this archetype)← your profile	WATCH-LIST	No indication. Don't take an SSRI you don't need. If PE ever became a concern, dapoxetine is the cleanest tool on the market — but the burden of proof is "actual PE distress lasting ≥4 weeks" before introducing this. Behavioral interventions (squeeze, start-stop, pelvic floor, partner communication) come first.
20-30 with confirmed lifelong or acquired PE← your profile	PRIMARY-PICK	for pharmacological treatment. 30 mg PRN. Combine with behavioral therapy. Reassess at 4 weeks.
30-50, PE complaint← your profile	PRIMARY-PICK	Same protocol. Watch CV history; not in men with significant cardiovascular disease.
30-50, comorbid PE + mild ED← your profile	PRIMARY-PICK	dapoxetine 30 mg + tadalafil 5-10 mg or sildenafil 50 mg, 1-2 h pre-activity.
50+, PE alone (rare — usually accompanied by ED in this group)← your profile	OPTIONAL-ADD	Caution with orthostatic risk; start at 30 mg; consider lower threshold to combine with PDE5i.
Anxiety-prone← your profile	NEUTRAL	Dapoxetine PRN doesn't carry the anxiety-amplification of chronic SSRI initiation; first-dose dizziness can feel anxiogenic but typically diminishes.
Depression-prone or on chronic SSRI← your profile	SKIP-FOR-NOW	unless washout completed. Direct stacking is unsafe. Dapoxetine alone is not an antidepressant — its short PK profile fails for chronic mood treatment.
High athletic load, tested status← your profile	NEUTRAL	not WADA-prohibited. No performance impact.
Combat-athlete (MMA / BJJ — the user)← your profile	WATCH-LIST	No indication. Notable that dapoxetine, unlike chronic SSRIs, doesn't blunt aggression / drive / competitive intensity at PRN dosing — so it's a much better fit for athletes if PE ever arose than off-label paroxetine or sertraline would be.
Strength/anabolic-focused← your profile	NEUTRAL	No HPG / testosterone impact at PRN exposure.

★20-30, brain-priority, high cognitive workload, no PE complaint (this archetype)
WATCH-LIST
← your profile
No indication. Don't take an SSRI you don't need. If PE ever became a concern, dapoxetine is the cleanest tool on the market — but the burden of proof is "actual PE distress lasting ≥4 weeks" before introducing this. Behavioral interventions (squeeze, start-stop, pelvic floor, partner communication) come first.
20-30 with confirmed lifelong or acquired PE
PRIMARY-PICK
← your profile
for pharmacological treatment. 30 mg PRN. Combine with behavioral therapy. Reassess at 4 weeks.
30-50, PE complaint
PRIMARY-PICK
← your profile
Same protocol. Watch CV history; not in men with significant cardiovascular disease.
30-50, comorbid PE + mild ED
PRIMARY-PICK
← your profile
dapoxetine 30 mg + tadalafil 5-10 mg or sildenafil 50 mg, 1-2 h pre-activity.
50+, PE alone (rare — usually accompanied by ED in this group)
OPTIONAL-ADD
← your profile
Caution with orthostatic risk; start at 30 mg; consider lower threshold to combine with PDE5i.
Anxiety-prone
NEUTRAL
← your profile
Dapoxetine PRN doesn't carry the anxiety-amplification of chronic SSRI initiation; first-dose dizziness can feel anxiogenic but typically diminishes.
Depression-prone or on chronic SSRI
SKIP-FOR-NOW
← your profile
unless washout completed. Direct stacking is unsafe. Dapoxetine alone is not an antidepressant — its short PK profile fails for chronic mood treatment.
High athletic load, tested status
NEUTRAL
← your profile
not WADA-prohibited. No performance impact.
Combat-athlete (MMA / BJJ — the user)
WATCH-LIST
← your profile
No indication. Notable that dapoxetine, unlike chronic SSRIs, doesn't blunt aggression / drive / competitive intensity at PRN dosing — so it's a much better fit for athletes if PE ever arose than off-label paroxetine or sertraline would be.
Strength/anabolic-focused
NEUTRAL
← your profile
No HPG / testosterone impact at PRN exposure.

▸ Subjective experience (deep)

Onset: 1-2 hours. Most men report a noticeable shift in ejaculatory threshold by the 90-minute mark.
Peak window: Hour 1.5 to hour 4. Effect on IELT is robust here.
Decline: Smooth fade over hours 4-12. Most users feel completely "off" by morning.
Hangover: Usually none. Some report light residual fatigue or grogginess if they used 60 mg.
Side-effect feel: First-time users get a wave of mild nausea (~20%) about 60-90 minutes in, occasionally with light-headedness if they took it on an empty stomach. Eating ~30 min before the dose dulls this substantially.
No cognitive blunting. Unlike chronic SSRIs at steady state, dapoxetine PRN doesn't produce emotional flattening or working-memory drag — concentration is well below the steady-state SERT saturation threshold.
Sexual side effects atypical for an SSRI. Libido and erection are not blunted; the drug is designed to extend latency only. Some men report heightened orgasm intensity once they cross the threshold; mechanism unclear.
Honest variability: ~10% of users tolerate it badly (severe nausea, syncope-like dizziness on first dose) and stop. ~5-10% get marginal benefit despite tolerability — these are usually the men who would do better on chronic paroxetine.

▸ Tolerance + cycling deep dive

Tolerance: None observed across 24-week extension trials. Effect maintained.
Cycle structure: Not cycled — PRN by design.
Dependence/withdrawal: None expected at intermittent use. EU post-marketing surveillance has not raised a withdrawal signal.

▸ Stacking deep dive

Synergistic with

Sildenafil / Tadalafil / Vardenafil (PDE5 inhibitors): Dapoxetine extends IELT, PDE5i ensures erection quality. Co-use for PE + mild ED is well-studied and recommended in some EU guidelines. No pharmacokinetic interaction. Watch additive BP-lowering on first co-dose.
Behavioral techniques (start-stop, squeeze, pelvic floor strengthening): Pharmacological + behavioral combination outperforms drug alone across trials.
Topical lidocaine/prilocaine sprays (on glans): Different mechanism (peripheral desensitization vs central serotonin); can layer for non-responders. Note: condom use protects partner from numbing transfer.

Avoid stacking with

MAOIs (phenelzine, tranylcypromine, linezolid, methylene blue, selegiline >10 mg/d): Absolute contraindication. 14-day washout each direction. Risk of fatal serotonin syndrome.
Other SSRIs / SNRIs / TCAs: Additive serotonergic load. If the user is already on a chronic SSRI for any indication, do not add dapoxetine — washout first.
Tramadol, meperidine, MDMA, mephedrone: Serotonergic stacking; serotonin syndrome risk.
5-HTP, L-tryptophan, St John's Wort: Same serotonergic concern.
Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, telithromycin, nefazodone): Raise dapoxetine AUC ~2x → increased syncope/orthostatic risk. EU label contraindicates strong inhibitors; cap at 30 mg with moderate inhibitors (erythromycin, diltiazem, verapamil, fluconazole).
Alcohol: Amplifies dizziness, syncope, CNS depression. EU label warns against combined use.
Recreational stimulants (MDMA, mephedrone, cocaine): Avoid; serotonergic + cardiovascular load.
Thioridazine (CYP2D6 substrate with QT effects): Contraindicated.

Neutral / safe co-administration

PDE5 inhibitors as noted (synergistic for combined PE + ED).
Most supplements the user is on (Mg, NAC, citicoline, PS, DHA, curcumin, rhodiola, theanine, glycine, D3/K2, beta-alanine, vit C) — no known interactions.
Modafinil — no known PK interaction; modafinil is a mild CYP2C19 inhibitor and dapoxetine clearance is mostly CYP3A4/CYP2D6 mediated. Theoretical low-magnitude interaction; clinically unimportant at PRN dapoxetine doses.
Caffeine — neutral.
Creatine — neutral.

▸ Drug interactions deep dive

Dapoxetine PK profile:

CYP3A4 + CYP2D6 primary metabolism. Active metabolite (desmethyl-dapoxetine) at low levels.
Weak CYP2D6 inhibitor itself.
Minimal CYP induction.

Clinically important interactions:

Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) — avoid (AUC ~2x). Moderate inhibitors (diltiazem, fluconazole, verapamil, erythromycin) — cap at 30 mg.
CYP2D6 poor metabolizers — slightly higher dapoxetine exposure; standard doses still tolerated but start at 30 mg.
Antihypertensives — additive orthostatic hypotension. First dose with extra caution.
Other SSRIs / serotonergic drugs — washout required (see Avoid Stacking).
PDE5 inhibitors — no PK interaction; additive BP effect.
Alcohol — significant CNS-depressive additivity (dizziness, syncope, sedation).

▸ Pharmacogenomics

CYP3A4 polymorphism: Modest exposure variability. Not a strong driver of clinical response.
CYP2D6 phenotype: PMs (~7-10% of Caucasians) have higher exposure; UMs lower. Genetic data from 23andMe (the user has this in pipeline for June 2026) will sharpen dose calibration if dapoxetine ever becomes relevant.
5-HT1A and SERT polymorphisms (5-HTTLPR S/L allele): Plausible link to PE phenotype itself; modulates baseline ejaculatory threshold. Not yet incorporated into clinical dosing decisions.
HLA-B alleles + SSRI hypersensitivity: No specific dapoxetine HLA-B SJS link reported (vs the well-known carbamazepine HLA-B*15:02 association). Class-typical SSRI sensitivity remains a watch item.

▸ Sourcing deep dive

Path	Vendor	Cost	Reliability	Notes
EU/UK/AU/CA pharmacy with Rx	Local pharmacy	$5-10/pill (Priligy 30 mg)	High	Cleanest path. Telehealth available in UK (Lloyds, Boots Online), AU, EU.
Indian online pharmacy (gray market)	Sun Pharma "Poxet", Cipla "Duralast", others	$0.50-2/pill	High (WHO-GMP)	Same channel as modafinil generics. ModafinilXL, BuyModa-successor vendors stock this routinely.
Indian fixed-dose combo (caution)	"Super P-Force" (dapoxetine + sildenafil), "Super Tadarise" (dapoxetine + tadalafil)	Varies	Medium	Convenient but harder to titrate each component. Use only after separately calibrating each drug.
US compounding / research-chem vendor	N/A reliable	Variable	Low	Not on FDA bulk substance lists; legit US compounding not legal. Avoid research-chem vendors — purity unverified, often adulterated formulations.
US telehealth	None mainstream	N/A	N/A	Not Rx-able in US; clinicians cannot legally prescribe.

For US-based users who need dapoxetine: the only practical paths are (a) traveling EU/UK/CA prescription, (b) Indian gray-market generic via the modafinil-style import channels. The Indian generic market is mature for Sun Pharma and Cipla brands. Pricing is dramatically below EU pharmacy.

▸ Biomarkers to track (deep)

Baseline (before first dose):
- IELT log (≥4 weeks of partner-recorded baseline if PE is the indication)
- Resting BP, orthostatic BP (lying → standing 1 min, 3 min)
- Resting HR, orthostatic HR
- Mood baseline (PHQ-9, optionally simple 1-10 VAS)
- Anxiety baseline (GAD-7 or 1-10 VAS)
- LFTs (ALT/AST) — covered in user's June 2026 panel
First few doses:
- First-dose: take seated/lying for first hour; record syncope/near-syncope events
- Side-effect log (nausea, dizziness, headache severity 1-10)
- IELT change (vs baseline)
- Subjective satisfaction + control PROs
Ongoing PRN use:
- IELT trend across 4-week chunks
- Side-effect tolerance check
- Mood scale every 2-4 weeks (rule out chronic-use anxiety/depression even at intermittent dosing)
- Annual LFT if used >1x/week sustained
Discontinuation:
- No formal taper monitoring; if used <1x/week intermittently, stopping is event-free.

▸ Controversies / open debates Live debate

"Why no FDA approval?" — Eli Lilly withdrew the antidepressant NDA in 2005 because efficacy in chronic depression was poor — a side effect of the rapid clearance, not bad pharmacology for PE. ALZA → Janssen → Menarini repositioned as PE-specific and pursued EU approval (granted 2009), but never re-submitted to FDA. Speculation: the US market for PE-specific drugs is smaller than the global market because US clinicians readily prescribe paroxetine off-label, and because the US insurance/regulatory pathway for a "lifestyle" indication is harder. Whatever the reason, US patients have to import.
"PRN ~3x IELT vs chronic paroxetine ~6-8x — is dapoxetine actually worth it?" — Yes, for most men, because the side-effect tax of chronic SSRI dosing (libido suppression, emotional blunting, weight gain, withdrawal, PSSD risk) is large and dapoxetine sidesteps almost all of it. Men who need maximal IELT extension and don't mind the chronic-SSRI burden can still go to paroxetine 20 mg/d.
"Syncope signal — overstated or real?" — Real but manageable. ~0.3-1.5% rate in trials; almost all first-dose; mitigated by sit/lie protocol on first dose.
"PSSD with dapoxetine?" — Theoretical concern raised because dapoxetine is structurally an SSRI. Real-world reports are scarce, plausibly because cumulative SERT exposure at PRN dosing is orders of magnitude lower than chronic SSRI use. Watch literature post-2025.
"Tadalafil/sildenafil + dapoxetine — extra BP risk?" — Mild additive hypotension on first co-dose. Studied combinations safe in trials when started low and with hydration.
"Why isn't this in US guidelines?" — Because it's not FDA-approved. AUA guidelines for PE list off-label SSRIs (paroxetine, sertraline, fluoxetine, clomipramine) and topical lidocaine; dapoxetine is mentioned but inaccessible domestically.

▸ Verdict change log

2026-05-10 — Initial verdict: WATCH-LIST / HIGH CONFIDENCE. No PE indication for users in this archetype. Captured because dapoxetine is the cleanest pharmacological tool for PE if it ever arose, and because as an on-demand SSRI it is the only SSRI in the wiki where the chronic-SSRI side-effect critique doesn't apply.

▸ Open questions / gaps Open

CYP2D6 / CYP3A4 status awaiting 23andMe results (June 2026). Will calibrate any future dose response.
Long-term PRN use safety beyond ~24 weeks — most trial extension data caps at 24 weeks. Real-world PAUSE-style cohorts go further but are observational.
PSSD risk at PRN dosing — theoretical, no real-world signal, but the mechanism makes it impossible to fully exclude.
Combined dapoxetine + low-dose daily tadalafil — under-studied; some clinicians do this for combined PE + sub-clinical ED in younger men.
Pediatric / adolescent — not approved, not studied.
Athlete performance impact in combat sports — no data; mechanism predicts no meaningful impact at PRN exposure.

✎

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load ▸

Loading…

Dapoxetine

Our depth — beyond the mirror

Synergistic with

Avoid stacking with

Neutral / safe co-administration

References

PMID 17011944

PMID 22247794

PMID 21696550

PMID 24433890

PMID 16855071

PMID 16413101

PMID 21214600

PMID 17536885

Priligy SmPC (UK / EMA)

EMA EPAR — Priligy

FDA Federal Register 2005 — withdrawal of dapoxetine NDA

WADA Prohibited List 2026

How was your experience with this compound?

See something off?

Educational research only.
Not medical advice.